TEM vs RLAY
TEM and RLAY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | TEMTempus AI, Inc. | RLAYRelay Therapeutics, Inc. |
|---|---|---|
| Market cap | $14.13M | $3.78B |
| P/B | 0.03 | — |
| P/S | 0.0x | 250.4x |
| Revenue | $1.51B(TTM) | — |
| Revenue growth (YoY) | 83.4% | 53.4% |
| Net income | -$189.27M(TTM) | — |
| Earnings growth (YoY) | 65.3% | 18.1% |
| EPS, diluted | $-1.06(TTM) | — |
| EBIT margin | -19.9% | -1971.6% |
| ROE | -49.0% | -31.1% |
| 1y total return | -12.0% | +146.1% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: TEM vs RLAY
| 지표 | TEM | RLAY |
|---|---|---|
| 최종 가치 | $19.5K | $23.6K |
| 총수익률 | +95.0% | +136.4% |
| CAGR | +32.3% | +43.4% |
| 변동성 | 97.1% | 77.5% |
| 샤프 | 0.72 | 0.78 |
| 소르티노 | 1.15 | 1.33 |
| 최대 낙폭 | -59.8% | -79.0% |
공통 거래일 598일 기준, 2024-06-14 → 2026-11-02 · 무위험수익률 4.16% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)